Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | DHODH | Q02127 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294945 | 0.84 | ANO1 (0.60) | MCL1NR4A2MAOBMAOAANO1 | |
| SCHEMBL3296263 | 0.83 | NR4A2 (0.67) | MCL1NR4A2MAOBMAOAMRGPRX4 | |
| SCHEMBL3299012 | 0.82 | NR4A2 (0.70) | NR4A2MRGPRX4 | |
| SCHEMBL2828539 | 0.81 | FFAR1 (0.69) | FFAR1 | |
| SCHEMBL3302205 | 0.79 | MRGPRX4 (0.60) | MCL1NR4A2MAOBMAOAMRGPRX4 | |
| SCHEMBL3301459 | 0.79 | MAOB (0.61) | MCL1NR4A2MAOBMAOAMRGPRX4 | |
| SCHEMBL3296016 | 0.78 | NR4A2 (0.54) | MCL1NR4A2MAOBMAOAMRGPRX4 | |
| SCHEMBL3299848 | 0.78 | MAOB (0.62) | MCL1NR4A2MAOBMAOAMRGPRX4 | |
| SCHEMBL3297208 | 0.78 | FFAR1 (0.61) | MCL1NR4A2MAOBMAOAANO1 | |
| SCHEMBL3296031 | 0.77 | MCL1 (0.47) | MCL1NR4A2MAOBMAOAANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | claimed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | ENPP2 818/4885MCL1 2555/4885NR4A2 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.